Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pivalamide SCHEMBL5177397 | 0.96 | BRAF (0.40) | BRAFABL1NR1H4 | |
| SCHEMBL5177405 | 0.95 | BRAF (0.39) | BRAFLMNA | |
| SCHEMBL4473791 | 0.90 | BRAF (0.40) | BRAFABL1NR1H4MEN1KMT2A | |
| SCHEMBL4479405 | 0.90 | BRAF (0.54) | BRAF | |
| SCHEMBL4463798 | 0.89 | BRAF (0.40) | BRAFLMNA | |
| SCHEMBL4476621 | 0.88 | MAPK14 (0.42) | BRAF | |
| Pivalamide SCHEMBL5177844 | 0.88 | BRAF (0.38) | BRAFABL1NR1H4MEN1KMT2A | |
| SCHEMBL5177857 | 0.87 | BRAF (0.38) | BRAFABL1NR1H4LMNA | |
| Pivalamide SCHEMBL5176151 | 0.85 | MAPK14 (0.40) | BRAF | |
| SCHEMBL5176158 | 0.84 | MAPK14 (0.39) | BRAFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485657-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | claimed |
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | claimed |
| US-7485657-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL2 | BRAF 4079/4885ABL1 1997/4885NR1H4 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.